IDEXX Laboratories (NASDAQ: IDXX) Reports Strong Quarterly Results, Exceeding Expectations
- IDEXX Laboratories surpassed analyst expectations for both earnings per share (EPS) and revenue in its latest quarterly report.
- Growth was significantly driven by a 15% increase in its Companion Animal Group and the success of new platforms like IDEXX Cancer Dx™.
- Following its fourth consecutive quarter of beating estimates, the company has raised its financial outlook for the full year 2026.
IDEXX Laboratories (NASDAQ: IDXX) is a company that specializes in animal diagnostics and healthcare. It provides a wide range of products and services for veterinarians around the world. With a market capitalization of approximately $45.19 billion, it is a major company in the pet healthcare industry.
Before the market opened, IDEXX Laboratories announced its quarterly results, beating analyst expectations. The company reported an earnings per share (EPS) of $3.47. This figure was higher than the analyst consensus estimate of $3.41, showing strong profitability for the quarter.
The company also posted total revenue of $1.14 billion, which surpassed the estimated $1.12 billion. As highlighted by Zacks, this revenue represents a 14% increase from the $998.43 million reported in the same quarter of the previous year.
This growth was primarily driven by a 15% increase in its Companion Animal Group. As noted in a release by Business Wire, the company's software, imaging, and its new IDEXX Cancer Dx™ platform are also gaining momentum and contributing to its success.
This report marks the fourth consecutive quarter that IDEXX Laboratories has exceeded estimates for both earnings and revenue. As a result of this sustained performance, the company has raised its financial outlook for the full year 2026, guiding for higher revenues and EPS.
Market news and analyst rating coverage
Gordon Thompson covers analyst rating changes, price-target updates, and company news for the FMP blog. His work focuses on summarizing the latest broker actions and market developments into accessible, data-driven updates for investors and analysts.
Financial data for every need
Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.
Create Free Account